A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT04634552

Public ClinicalTrials.gov record NCT04634552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 9, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Study identification

NCT ID: NCT04634552
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Janssen Research & Development, LLC; Industry
Enrollment: 510 participants

Conditions and interventions

Conditions

Hematological Malignancies

Interventions

Talquetamab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2021
Primary completion: Jun 29, 2027
Completion: Mar 29, 2029
Last update posted: May 7, 2026

2021 – 2029

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of Alabama Birmingham	Birmingham	Alabama	35294	Recruiting
University of Arkansas for Medical Sciences	Little Rock	Arkansas	72205	Recruiting
City of Hope	Duarte	California	91010	Completed
Memorial Healthcare System	Hollywood	Florida	33021	Recruiting
Emory University Winship Cancer Institute	Atlanta	Georgia	30322	Recruiting
University of Chicago	Chicago	Illinois	60637	Recruiting
Norton Cancer Institute	Louisville	Kentucky	40207	Recruiting
University of Michigan Health System	Ann Arbor	Michigan	48109	Recruiting
Washington University School Of Medicine	St Louis	Missouri	63110	Recruiting
NYU Langone Health	New York	New York	10016	Active, not recruiting
Mount Sinai Medical Center	New York	New York	10023	Recruiting
University of Rochester Medical Center	Rochester	New York	14642	Recruiting
Providence Portland Medical Center	Portland	Oregon	97213	Completed
Tennessee Oncology	Nashville	Tennessee	37203	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04634552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 7, 2026 · Synced May 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04634552 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →